Goswami B C, Baishya B, Barua A B, Olson J A
Department of Chemistry, Gauhati University, Guwahati, India.
Skin Pharmacol Appl Skin Physiol. 1999 Jul-Aug;12(4):167-73. doi: 10.1159/000066240.
Topical retinoyl beta-glucuronide (RBG) is beneficial in the treatment of mild to moderate acne (acne vulgaris) in patients largely of North-European origin in the US. Because the skin types of people in India are different from those in the US, we investigated the effectiveness and toxicity of topical RBG in acne patients in India. Each day, 27 acne patients were treated topically with the vehicle, and 39 acne patients were treated topically with 0. 16% RBG cream for 18 weeks in a double-blind study. A significant reduction (p < 0.001) in total lesions, inflammatory lesions and noninflammatory lesions in patients treated with RBG as compared with the vehicle only (86.8, 80.2 and 94.6% vs. 40.1, 34.3 and 50%, respectively) was observed. No side effects were associated with topical RBG treatment. Thus, topical 0.16% RBG is a rapid, effective and nontoxic treatment for mild to moderate acne in Asian-Indian patients.
局部用视黄醇β - 葡萄糖醛酸苷（RBG）对美国主要为北欧血统的患者治疗轻至中度痤疮（寻常痤疮）有益。由于印度人的皮肤类型与美国人不同，我们研究了局部用RBG对印度痤疮患者的有效性和毒性。在一项双盲研究中，每天有27名痤疮患者局部使用赋形剂治疗，39名痤疮患者局部使用0.16%的RBG乳膏治疗，为期18周。与仅使用赋形剂的患者相比，使用RBG治疗的患者在总皮损、炎性皮损和非炎性皮损方面有显著减少（p < 0.001）（分别为86.8%、80.2%和94.6%，对比40.1%、34.3%和50%）。局部用RBG治疗未出现副作用。因此，局部用0.16%的RBG是治疗亚洲印度患者轻至中度痤疮的一种快速、有效且无毒的方法。
